Inhibition or deletion of angiotensin II type 1 receptor suppresses elastase-induced experimental abdominal aortic aneurysms

Clinical trials testing the ability of the angiotensin receptor blocker telmisartan to suppress early abdominal aortic aneurysm disease progression are ongoing. This study investigates the potential mechanisms by which telmisartan may limit abdominal aortic aneurysm disease progression.